Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP).
These recommendations include information on use of two vaccines recently licensed for use with infants: Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate) (HbOC), manufactured by Praxis Biologics, Inc., and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PRP-OMP), manufactured by Merck Sharp and Dohme, newly licensed for use with infants. This statement also updates recommendations for use of these and other Haemophilus b conjugate vaccines with older children and adults.
D000328:Adult; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000009:adverse effects; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000009:adverse effects; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D002675:Child, Preschool; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007223:Infant; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000009:adverse effects; D014611:Vaccination / Q000592:standards
D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; C061963:HibTITER protein, Haemophilus influenzae